Potentiation of simian immunodeficiency virus (SIV)-speciific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen

被引:72
作者
Hel, Z
Tsai, WP
Thornton, A
Nacsa, J
Giuliani, L
Tryniszewska, E
Poudyal, M
Venzon, D
Wang, XC
Altman, J
Watkins, DI
Lu, WH
von Gegerfelt, A
Felber, BK
Tartaglia, J
Pavlakis, GN
Franchini, G
机构
[1] NCI, Basic Res Lab, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA
[3] Emory Univ, Vaccine Ctr Yerkes, Atlanta, GA 30329 USA
[4] Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA
[5] Aventis Pasteur, Toronto, ON, Canada
关键词
D O I
10.4049/jimmunol.167.12.7180
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cell-mediated immune responses play an important role in the containment of HIV-1 replication. Therefore, an effective vaccine against HIV-1 should be able to elicit high frequencies of virus-specific CD8(+) and CD4(+) T cells. The highly attenuated poxvirus-based vaccine candidate, NYVAC-SIV-gag-pol-env (NYVAC-SIV-gpe), has been shown to induce and/or expand SIV-specific CD4(+) and CD8(+) T cell responses in both naive and infected macaques. In this study, the immunogenicity of NYVAC-SIV-gpe alone was compared with a combination regimen where printing with an optimized DNA-SIV-gag-env vaccine candidate was followed by a NYVAC-SIV-gpe boost. In macaques immunized with the prime-boost regimen, the extent and durability of CD8(+) T cell response to an immunodominant SIV gag epitope was increased and these animals recognized a broader array of subdominant SIV epitopes in the cytolytic assay. In addition, the prime-boost regimen significantly enhanced the proliferative responses to both SIV gag and env proteins. Thus, the combination of these vaccine modalities may represent a valuable strategy in the development of a vaccine for HIV.
引用
收藏
页码:7180 / 7191
页数:12
相关论文
共 71 条
[1]   HIV-1 RECOMBINANT POXVIRUS VACCINE INDUCES CROSS-PROTECTION AGAINST HIV-2 CHALLENGE IN RHESUS MACAQUES [J].
ABIMIKU, AG ;
FRANCHINI, G ;
TARTAGLIA, J ;
ALDRICH, K ;
MYAGKIKH, M ;
MARKHAM, PD ;
CHONG, PL ;
KLEIN, M ;
KIENY, MP ;
PAOLETTI, E ;
GALLO, RC ;
ROBERTGUROFF, M .
NATURE MEDICINE, 1995, 1 (04) :321-329
[2]  
Abimiku AG, 1997, AIDS RES HUM RETROV, V15, pS78
[3]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[4]   Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen [J].
Allen, TM ;
Vogel, TU ;
Fuller, DH ;
Mothé, BR ;
Steffen, S ;
Boyson, JE ;
Shipley, T ;
Fuller, J ;
Hanke, T ;
Sette, A ;
Altman, JD ;
Moss, B ;
McMichael, AJ ;
Watkins, DI .
JOURNAL OF IMMUNOLOGY, 2000, 164 (09) :4968-4978
[5]  
Allen TM, 1998, J IMMUNOL, V160, P6062
[6]   CD8+ lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule Mamu-A*01:: Implications for vaccine design and testing [J].
Allen, TM ;
Mothé, BR ;
Sidney, J ;
Jing, PC ;
Dzuris, JL ;
Liebl, ME ;
Vogel, TU ;
O'Connor, DH ;
Wang, XC ;
Wussow, MC ;
Thomson, JA ;
Altman, JD ;
Watkins, DI ;
Sette, A .
JOURNAL OF VIROLOGY, 2001, 75 (02) :738-749
[7]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[8]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[9]   Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].
Baba, TW ;
Liska, V ;
Hofmann-Lehmann, R ;
Vlasak, J ;
Xu, WD ;
Ayehunie, S ;
Cavacini, LA ;
Posner, MR ;
Katinger, H ;
Stiegler, G ;
Bernacky, BJ ;
Rizvi, TA ;
Schmidt, R ;
Hill, LR ;
Keeling, ME ;
Lu, YC ;
Wright, JE ;
Chou, TC ;
Ruprecht, RM .
NATURE MEDICINE, 2000, 6 (02) :200-206
[10]   Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251:: Dependence on route of challenge exposure [J].
Benson, J ;
Chougnet, C ;
Robert-Guroff, M ;
Montefiori, D ;
Markham, P ;
Shearer, G ;
Gallo, RC ;
Cranage, M ;
Paoletti, E ;
Limbach, K ;
Venzon, D ;
Tartaglia, J ;
Franchini, G .
JOURNAL OF VIROLOGY, 1998, 72 (05) :4170-4182